Prizloncabtagene Autoleucel

Phase 2Cell therapy

Johnson & Johnson

Prizloncabtagene Autoleucel is one of 63 biologic programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaRecruiting

Large B-Cell LymphomaNot yet recruiting

Lymphoma, Non-HodgkinActive, not recruiting

LymphomaPhase 2

Recruiting

Large B-Cell LymphomaPhase 2

Not yet recruiting

Lymphoma, Non-HodgkinPreclinical

Active, not recruiting

Competition

Competitive Landscape

370 competitors in Lymphoma

#DrugCompanyPhaseTrials

Prizloncabtagene Autoleucel

Johnson & Johnson

Phase 2

4 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Cabenuva

GSK

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Lymphoma

NCT05800977

Q4 2030

Phase 2Not yet recruiting

Large B-Cell Lymphoma

NCT07875413

Q3 2041

PreclinicalActive, not recruiting

Lymphoma, Non-Hodgkin

NCT05421663

Clinical

Trials by Indication[1]

Lymphoma4 trials

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

Completed·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT04696432·7 enrolled

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Recruiting·SShanghai AbelZeta Ltd.·Phase 1/2·NCT05800977·112 enrolled

A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 1·NCT04693676·17 enrolled

Show 1 more trial

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

Completed·PPeking Union Medical College Hospital·Phase 1·NCT04655677·10 enrolled

Safety and Efficacy1 trial

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

Completed·SShanghai Tongji Hospital, Tongji University School of Medicine·Phase 1·NCT04317885·25 enrolled

Lymphoma, Non-Hodgkin1 trial

A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Preclinical·NCT05421663·166 enrolled

Large B-cell Lymphoma1 trial

A Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy, Prizloncabtagene Autoleucel (Prizlon-cel), for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Not yet recruiting·AAbelZeta Inc.·Phase 2·NCT07875413·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Prizloncabtagene Autoleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prizloncabtagene Autoleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prizloncabtagene Autoleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

Prizloncabtagene Autoleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2030

Q3 2041

Trials by Indication[1]

Lymphoma4 trials

Safety and Efficacy1 trial

Lymphoma, Non-Hodgkin1 trial

Large B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News